Otros idiomas Hubei Biocause Pharmaceutical Co., Ltd.

Acciones

000627

CNE000000F48

Precio de cierre Shenzhen S.E. Otros sitios de cotización 00:00:00 08/05/2024			Varia. Cinco días.	Varia. 1 de enero.
2,29 ^CNY	-3,78 %		-3,78 %	-19,37 %

29/04	Hubei Biocause Pharmaceutical Co. presenta los resultados del primer trimestre finalizado el 31 de marzo de 2024	CI
15/04	Hubei Biocause Pharmaceutical Co. presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Biocause Pharma’s Insurance Unit Posts Steady Annual Premium in 2023	15/01
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Hubei Biocause Pharmaceutical Co., Ltd. agreed to acquire 60% stake in Huarui Insurance Sales Co.,Ltd. for approximately CNY 150 million.	22/09/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23
Biocause Pharma Unit Logs 31 Million Yuan Insurance Premium Income in January-July Period	14/08/23
Biocause Pharma Unit Generates 24 Billion Yuan Premium Income in January-May Period	12/06/23
Hubei Biocause Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 30 May 2023	22/05/23
Biocause Pharma’s Life Insurance Unit Generates 22 Billion Yuan in January-April Premium Income	16/05/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2022	24/04/23
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/04/23
Hubei Biocause Pharmaceutical Gets Regulatory Nod for Ibuprofen; Shares Down 5%	30/12/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22
Biocause Heilen Pharma to Unlock 1.21% Restricted Stake	20/06/22
Hubei Biocause Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on June 2, 2022	24/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	05/05/22
Hubei Biocause Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	29/04/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Hubei Biocause Pharmaceutical Co., Ltd.

Acciones

000627

CNE000000F48

Otros idiomas

Filtros